BIOMEDICINE & PHARMACOTHERAPY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-07-09 14862b90m09(暂无昵称) 来自上海

偏重的研究方向：分子生物学
经验分享：很慢，6/15号投稿，至今仍然submitted

19 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-07-10 enamal 来自重庆

偏重的研究方向：微生物
经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？

20 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-07-03 ms4000000529451557 来自河南省

偏重的研究方向：肿瘤
经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。

18 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2023-07-31 ms6000001702952186 来自湖南省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：分子生物学;肿瘤;综述
经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运

64 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2023-09-04 ms5000000678442882 来自天津

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：综述
经验分享：6.28 submit
7.12 with editor
7.14 under review
8.7 revise
8.21 revision submited to journal
8.23 under review
9.1 accept

66 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-07-11 ms6000001868692722 来自黑龙江省

我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛

17 0

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2023-12-15 147ddcd3m55暂无昵称来自北京

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;综述
经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。

48 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-07-09 122f5223m97(暂无昵称) 来自吉林省

小伙伴们，最近with editor 到多少号了，求告知

22 0

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-06-19 坐敷锦来自辽宁省

6月6投的，6月19还是Submitted to Journal```怎么这么慢

28 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2214139, encodeId=99c72214139bc, content=偏重的研究方向：分子生物学 经验分享：很慢，6/15号投稿，至今仍然submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf9c5290959, createdName=14862b90m09(暂无昵称), createdTime=Tue Jul 09 20:28:49 CST 2024, time=2024-07-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2214261, encodeId=0c902214261f9, content=偏重的研究方向：微生物 经验分享：6.28投的，至今仍然是Submitted to Journal，需要发邮件催催吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/D009B9CAE35EB6302466FC0A929E4380/100, createdBy=bdb32411544, createdName=enamal, createdTime=Wed Jul 10 14:26:41 CST 2024, time=2024-07-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2212925, encodeId=e3cf22129254b, content=偏重的研究方向：肿瘤 经验分享：综述，6月11号投稿的，7月3号还是submitted to journal，5xxx号，跪求心软编辑和审稿人，求求了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db776430639, createdName=ms4000000529451557, createdTime=Wed Jul 03 10:13:32 CST 2024, time=2024-07-03, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2150651, encodeId=23c5215065191, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：分子生物学;肿瘤;综述 经验分享：接收了一篇综述，6.4投稿，7.12回来意见。7.28翻修，7.30接收。真幸运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bb45610969, createdName=ms6000001702952186, createdTime=Mon Jul 31 17:04:28 CST 2023, time=2023-07-31, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2155986, encodeId=1fc3215598632, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：综述 经验分享：6.28 submit 7.12 with editor 7.14 under review 8.7 revise 8.21 revision submited to journal 8.23 under review 9.1 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345a8188867, createdName=ms5000000678442882, createdTime=Mon Sep 04 09:42:22 CST 2023, time=2023-09-04, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2214383, encodeId=61fe221438300, content=我想问一下大家，这个是一定需要画APC的费用的对吧，两万多嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c686507416, createdName=ms6000001868692722, createdTime=Thu Jul 11 10:01:46 CST 2024, time=2024-07-11, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2175017, encodeId=05c721e5017e2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;综述 经验分享：66**号，第二次投稿(8月初第一次没找到审稿人，一个月拒了，说欢迎修改题目和关键词后重投)，第二次投稿邀请了25个人，终于找到了一个审稿人愿意审稿，小修了2次(相当于这个审稿人审了3次文章)，每次都是审10天左右，然后等编辑5天左右做决定，也就是一次修稿周期就得20天，今天终于接收了。9月18号投的稿。送审之后修回的概率很大，对大而不精的综述特别友好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/20/36e4b1345247d92b63b923885e50e463.jpg, createdBy=921d5250503, createdName=147ddcd3m55暂无昵称, createdTime=Fri Dec 15 01:05:53 CST 2023, time=2023-12-15, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2214071, encodeId=1e2822140e103, content=小伙伴们，最近with editor 到多少号了，求告知, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12902371838, createdName=122f5223m97(暂无昵称), createdTime=Tue Jul 09 13:46:07 CST 2024, time=2024-07-09, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2210733, encodeId=b6952210e332b, content=6月6投的，6月19还是Submitted to Journal```怎么这么慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBFMhfUxWGFlC0H0yG1ibTnKxgXEYfA4remwtQ8Y1W5l5EwnxawChADQpPHFvZibrJMezsFEQgR7soXFY85NlmeQ/132, createdBy=41d22323925, createdName=坐敷锦, createdTime=Wed Jun 19 23:24:09 CST 2024, time=2024-06-19, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2212121, encodeId=97752212121bb, content=记录一下 6月15号投稿，6月28号还是Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d768343641, createdName=ms1000000212761733, createdTime=Fri Jun 28 15:53:49 CST 2024, time=2024-06-28, status=1, ipAttribution=)]

2024-06-28 ms1000000212761733

记录一下
6月15号投稿，6月28号还是Submitted to Journal

22 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务